Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the US and Canada, To Pay Bausch + Lomb Ireland Limited an Upfront Payment Consisting of $2M in Cash and $3M in Shares
Portfolio Pulse from Benzinga Newsdesk
Eyenovia, Inc. has re-acquired the development and commercialization rights to MicroPine in the U.S. and Canada from Bausch + Lomb Ireland Limited. MicroPine is an investigational spray for pediatric progressive myopia, a condition affecting over 25 million children in the U.S. The re-acquisition enhances Eyenovia's phase III pipeline and commercial prospects, potentially doubling the asset value of the MicroPine program. Eyenovia will pay $2M in cash and $3M in shares upfront, plus future royalties on net sales.
January 16, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eyenovia's re-acquisition of MicroPine rights could significantly boost its phase III pipeline and commercial potential, especially with the anticipated FDA approval of other products. The deal's upfront payment and future royalties indicate a strong commitment to MicroPine's success.
The re-acquisition of MicroPine rights by Eyenovia is a significant strategic move, indicating the company's confidence in the product's market potential and its commitment to expanding its commercial portfolio. The payment structure, including both cash and stock, suggests a strong belief in the long-term value of MicroPine. The potential doubling of the asset value and the upcoming FDA approvals for other products could lead to increased investor interest and a positive short-term impact on Eyenovia's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100